Adjusted Didanosine

For wt under 60 kg

Loading...

For wt under 60 kg

References

  1. Rajesh T Gandhi. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel.. JAMA, 2025
  2. E. Negredo. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS, 2004
  3. M. Murphy. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003
  4. A. Schindzielorz. Rates and risk factors for adverse events associated with didanosine in the expanded access program.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1994
  5. J. Allan. Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1993
  6. J. O. Kahn. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.. The New England journal of medicine, 1992
  7. Eric Singlas. Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis. Antimicrobial Agents and Chemotherapy, 1992